| Description | Emiglitate is a selective and competitive α-glucoside hydrolase inhibitor. |
| In vitro | Emiglitate inhibits the glucose-stimulated insulin release in parallel. It also has an inhibitory effect on the activities of acid glucan-1,4-α-glucosidase and acid α-glucosidase. The CO-induced amplification of the glucose-stimulated insulin release as well as of the increased activities of the acid α-glucoside hydrolases are abrogated by emiglitate. Which showed the same levels as in the absence of CO. The CO-induced rise in the activities of acid phosphatase and acid N-acetyl-β-D-glucosaminidase is not appreciably affected by emiglitate. The activities of acid phosphatase and N-acetyl-β-D-glucosaminidase tend to increase in the presence of the α-glucoside hydrolase inhibitor [1]. |
| In vivo | Emiglitate in the amount of 5 mg/kg b.wt. does not induce significant changes either of glycogen concentrations or at the EM-level. Emiglitate causes a significant, dose-dependent increase of hepatic glycogen concentrations, in fasted rats. The increase in hepatic glycogen is due to lysosomal storage of glycogen only [2]. |
| Synonyms | BAY o 1248 |
| molecular weight | 355.38 |
| Molecular formula | C17H25NO7 |
| CAS | 80879-63-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| References | 1. Mosén H, et al. Nitric oxide inhibits, and carbon monoxide activates, islet acid alpha-glucoside hydrolase activitiesin parallel with glucose-stimulated insulin secretion. J Endocrinol. 2006 Sep;190(3):681-93. 2. Lembcke B, et al. Lysosomal storage of glycogen as a sequel of alpha-glucosidase inhibition by the absorbed deoxynojirimycin derivative emiglitate (BAYo1248). A drug-induced pattern of hepatic glycogen storage mimicking Pompe's disease (glycogenosis type II). Res Exp Med (Berl). 1991;191(6):389-404. |